Standard Chemoimmunotherapy (FCR/BR) Versus Rituximab + Venetoclax (RVe) Versus Obinutuzumab (GA101) + Venetoclax (GVe) Versus Obinutuzumab + Ibrutinib + Venetoclax (GIVe) in Fit Patients With Previously Untreated Chronic Lymphocytic Leukemia (CLL) Without Del(17p) or TP53 Mutation

Clinical trial NCT02950051 · COMPLETED

Trial details

NCT number: NCT02950051
Sponsor: German CLL Study Group
Status: COMPLETED
Phase: Phase 3
Study type: INTERVENTIONAL

Chronic Lymphocytic Leukemia

Start date: 2016-12-13
Primary completion: 2024-02-29
Enrollment: 926

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.